Potency of PD-1 and CTLA -4 Bispecific or combination in humanized Mouse Model Dr. Richard Stebbings

CTLA4 and attenuation of T cell responseПодробнее

MEDI5752: First-in-human trial of a novel PD-1 and CTLA-4 bispecific checkpoint inhibitorПодробнее

Cancer immunotherapy | The PD-L1 pathwayПодробнее

How PARP inhibitors (PARPi) workПодробнее

Future research directions for the novel PD-1 and CTLA-4 bispecific checkpoint inhibitor, MEDI5752Подробнее

3-D IHC: Mouse spleen - CD4, CD169 (Siglec-1), CD45R/B220Подробнее

MEDI5752: Novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumorsПодробнее

Immune Checkpoint Inhibitors, The Next Generation Cancer Therapy - Creative BiolabsПодробнее

Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple MyelomaПодробнее

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathwaysПодробнее

Anti-PD-1 or anti-CTLA-4 in first line therapy?Подробнее

Exploring the Combination Anti-CTLA-4 and Anti-PD-1 in Multiple Myeloma Post-TransplantПодробнее

Cancer Immunotherapy - PD-1 and PD-L1Подробнее

Combining CTLA-4 Agents With PD-1/PD-L1 Agents in Lung CancerПодробнее

Pros and cons of immune checkpoint inhibitors for tumor immunotherapyПодробнее

CD4 T lymphocytes presence revealed in the healthy mouse brainПодробнее

PD-1 Immunotherapy explained in under 2 minutes!Подробнее

PD1/ CTLA4 : Upfront or sequentially?Подробнее

Immunotherapy: Moving beyond PD1 and PDL1 inhibitorsПодробнее